20:35 EDT Cathie Wood’s ARK Investment buys 329K shares of Crispr Therapeutics (CRSP) today
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $79 from $80 at BofA
- Crispr Therapeutics AG: Strong Buy Rating Backed by Promising Clinical Data and Strategic Collaborations
- Crispr Therapeutics AG: Promising Trial Results and Strong Financial Position Support Buy Rating
- Crispr Therapeutics upgraded to Buy from Hold at Clear Street
- Crispr Therapeutics AG: Balancing Growth Potential with Profitability Challenges – Hold Rating